Sensei Biotherapeutics (NASDAQ:FTH) Reaches New 12-Month High – Here’s Why

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) reached a new 52-week high on Tuesday . The stock traded as high as $41.16 and last traded at $40.9250, with a volume of 274991 shares traded. The stock had previously closed at $40.05.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Loop Capital set a $50.00 price objective on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Citizens Jmp initiated coverage on shares of Sensei Biotherapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Wall Street Zen raised Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Sensei Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Trading Up 1.3%

The company has a fifty day moving average price of $30.19. The company has a market capitalization of $1.05 billion, a PE ratio of -0.29 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, sell-side analysts predict that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Brian C. Stephenson purchased 5,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were purchased at an average cost of $23.50 per share, with a total value of $117,500.00. Following the purchase, the chief financial officer directly owned 46,688 shares in the company, valued at approximately $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 49,494 shares of company stock worth $1,188,822. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after acquiring an additional 1,100 shares during the last quarter. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Bank of America Corp DE boosted its stake in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Finally, Alyeska Investment Group L.P. acquired a new position in Sensei Biotherapeutics in the 2nd quarter valued at $3,610,000. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.